Chinese biopharmaceutical company Alphamab Oncology has raised $60 million in a Series B financing round, led by Hudson Bay Capital Management LP, a US and UK-based asset management firm.
The round was joined by new investors including entrepreneur Adrian Cheng, and existing institutional backers such as China Venture Capital Fund (CVC), Hong Kong-based private equity firm PAG, and VC firm Advantech Capital, according to an announcement.
